Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need

Naveen Pemmaraju, Hagop Kantarjian, Kendra Sweet, Eunice Wang, Jayastu Senapati, Nathaniel R. Wilson, Marina Konopleva, Arthur E. Frankel, Vikas Gupta, Ruben Mesa, Matthew Ulrickson, Edward Gorak, Sumeet Bhatia, Tulin Budak-Alpdogan, James Mason, Maria Teresa Garcia-Romero, Norma Lopez-Santiago, Gabriela Cesarman-Maus, Pankit Vachhani, Sangmin Lee, Vijaya Raj Bhatt, William Blum, Roland B. Walter, Dale Bixby, Ivana Gojo, Madeleine Duvic, Raajit K. Rampal, Marcos de Lima, James Foran, Amir T. Fathi, Aric Cameron Hall, Meagan A. Jacoby, Jeffrey Lancet, Gabriel Mannis, Anthony S. Stein, Alice Mims, David Rizzieri, Rebecca Olin, Alexander Perl, Gary Schiller, Paul Shami, Richard M. Stone, Stephen Strickland, Matthew J. Wieduwilt, Naval Daver, Farhad Ravandi, Sumithira Vasu, Monica Guzman, Gail J. Roboz, Joseph Khoury, Muzaffar Qazilbash, Phyu P. Aung, Branko Cuglievan, Yazan Madanat, Mohamed A. Kharfan-Dabaja, Anna Pawlowska, Justin Taylor, Martin Tallman, Prajwal Dhakal, Andrew A. Lane

Blood (2023) 141 (6): 567–578.

https://doi.org/10.1182/blood.2022017865

Published: 2023

Journal Articles

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

Blood (2017) 130 (6): 722–731.

https://doi.org/10.1182/blood-2017-04-779405

Published: 2017

Includes: Supplemental data

Journal Articles

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Large Single-Center Experience: Analysis of Clinical and Molecular Characteristics and Patient Outcomes

Naveen Pemmaraju, MD, Hagop M. Kantarjian, MD, Jorge E. Cortes, MD, Madeleine Duvic, MD, Joseph D Khoury, MD, Keyur Patel, MD, Naval Daver, MD, Susan O'Brien, MD, Sherry Pierce, BSN, BA, Guillermo Garcia-Manero, MD, Elias Jabbour, Nitin Jain, MD, Stefan Faderl, MD, Deborah Thomas, MD, Arthur E. Frankel, MD, Muzaffar H. Qazilbash, MD, Marina Konopleva, MD PhD

Blood (2015) 126 (23): 3746.

https://doi.org/10.1182/blood.V126.23.3746.3746

Published: 2015

Journal Articles

Safety and Efficacy of AG-221, a Potent Inhibitor of Mutant IDH2 That Promotes Differentiation of Myeloid Cells in Patients with Advanced Hematologic Malignancies: Results of a Phase 1/2 Trial

Blood (2015) 126 (23): 323.

https://doi.org/10.1182/blood.V126.23.323.323

Published: 2015

Journal Articles

Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients

Arthur E. Frankel, Jung H. Woo, Chul Ahn, Naveen Pemmaraju, Bruno C. Medeiros, Hetty E. Carraway, Olga Frankfurt, Stephen J. Forman, Xuezhong A. Yang, Marina Konopleva, Francine Garnache-Ottou, Fanny Angelot-Delettre, Christopher Brooks, Michael Szarek, Eric Rowinsky

Blood (2014) 124 (3): 385–392.

https://doi.org/10.1182/blood-2014-04-566737

Published: 2014

Journal Articles

Preclinical Studies Of SL-401, a Targeted Therapy Directed To The Interleukin-3 Receptor (IL3-R), In Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Potent Activity In BPDCN Cell Lines, Primary Tumor, and In An In Vivo Model

Delettre Fanny, PhD, Arthur E. Frankel, MD, Estelle Seilles, PhD, Sabeha Biichle, Bsc, Eric Deconninck, MD, Francis Bonnefoy, PhD, Baptiste Lamarthee, PhD Student, Christopher L. Brooks, PhD, Eric Rowinsky, MD, Philippe Saas, Ph.D., Francine Garnache Ottou, PhD

Blood (2013) 122 (21): 3942.

https://doi.org/10.1182/blood.V122.21.3942.3942

Published: 2013

Journal Articles

An Update On The Robust Clinical Activity Of SL-401, a Targeted Therapy Directed To The Interleukin-3 Receptor On Cancer Stem Cells and Tumor Bulk, In Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Arthur E. Frankel, MD, Jung H. Woo, PhD, Jeremy P. Mauldin, PhD, Hetty E. Carraway, MD, MBA, Olga Frankfurt, MD, Stephen J. Forman, MD, Sumithira Vasu, MBBS, Naveen Pemmaraju, MD, Marina Konopleva, MD, PhD, Donna E. Hogge, MD, PhD, FRCPC, Francine Garanache-Ottou, Ph.D., Fanny Angelot-Delettre, PhD, Christopher Brooks, PhD, Michael Szarek, PhD, Ivan Bergstein, MD, Eric Rowinsky, MD

Blood (2013) 122 (21): 2682.

https://doi.org/10.1182/blood.V122.21.2682.2682

Published: 2013

Journal Articles

An Update On The Clinical Activity Of Resimmune, a Targeted Therapy Directed To CD3 Receptor, In Patients With Cutaneous T Cell Lymphomas--CTCL

Arthur E. Frankel, MD, Jung H Woo, PhD, Jeremy P Mauldin, PhD, Francine M. Foss, MD, Madeleine Duvic, MD, David M Neville, Jr., MD

Blood (2013) 122 (21): 4381.

https://doi.org/10.1182/blood.V122.21.4381.4381

Published: 2013

Journal Articles

SL-401, A Targeted Therapy Directed to the Interleukin-3 Receptor Present On Leukemia Blasts and Cancer Stem Cells, Is Active As a Single Agent in Patients with Advanced AML

Marina Konopleva, MD, PhD, Donna E. Hogge, MD, PhD, FRCPC, David A. Rizzieri, MD, Thomas P. Cirrito, PhD, Steven M. Kornblau, MD, PhD, Gautam Borthakur, M.D., Carol Bivins, RN, Guillermo Garcia-Manero, MD, Tapan M. Kadia, M.D., Farhad Ravandi, MD, Michael Andreeff, MD, PhD, Jorge E. Cortes, MD, Kenneth Hoberman, Michael Szarek, PhD, Eric Rowinsky, MD, Ivan Bergstein, MD, Hagop M. Kantarjian, MD, Arthur E. Frankel, MD

Blood (2012) 120 (21): 3625.

https://doi.org/10.1182/blood.V120.21.3625.3625

Published: 2012

Journal Articles

The IL-3Rα-Targeted Drug SL-401 Selectively Kills Blastic Plasmacytoid Dendritic Cell Neoplasm Cells

Fanny Angelot-Delettre, PhD, Arthur E. Frankel, MD, Jen Sing Liu, PhD, Estelle Seilles, PhD, Sabeha Biichle, Bsc, Bernard Drenou, MD, PhD, Mark L. Jacobson, MA, Thomas P. Cirrito, PhD, Arkam Yazid, MD, Eric Deconinck, MD, PhD, Christopher L. Brooks, PhD, Philippe Saas, PhD, Francine Garnache Ottou, PhD

Blood (2011) 118 (21): 2588.

https://doi.org/10.1182/blood.V118.21.2588.2588

Published: 2011

Journal Articles

IL3R Directed Agents, SL-401 and SL-501, Inhibit the Growth of Leukemia Stem Cells In CML.

Olga Frolova, MD, PhD, Arthur E Frankel, MD, Borys Korchin, MD, PhD, Jorge Cortes, MD, Hagop M. Kantarjian, MD, Michael Andreeff, MD, Ph.D., Marina Konopleva, MD, PhD

Blood (2010) 116 (21): 3403.

https://doi.org/10.1182/blood.V116.21.3403.3403

Published: 2010

Journal Articles

Phase I Trial Results for SL-401, a Novel Cancer Stem Cell (CSC) Targeting Agent, Demonstrate Clinical Efficacy at Tolerable Doses In Patients with Heavily Pre-Treated AML, Poor Risk Elderly AML, and High Risk MDS

Blood (2010) 116 (21): 3298.

https://doi.org/10.1182/blood.V116.21.3298.3298

Published: 2010

Journal Articles

Targeting IL3 Receptor in Chronic Myeloid Leukemia.

Olga Frolova, MD, PhD, Rui-Yu Wang, MD, PhD, Borys Korchin, Julie C. Watt, Jorge Cortes, MD, Arthur E. Frankel, MD, Hagop M. Kantarjian, MD, Michael Andreeff, MD, PhD, Marina Konopleva, MD, PhD

Blood (2009) 114 (22): 2172.

https://doi.org/10.1182/blood.V114.22.2172.2172

Published: 2009

Journal Articles

Phase I Study Demonstrates Activity and Tolerability of Diphtheria Toxin Interleukin-3 Fusion Protein in Patients with AML and MDS.

Arthur E. Frankel, MD, E.R. Smith, T.A. George, J.S. Liu, PhD, J. Lee, S.K. Park, MD, David A. Rizzieri, MD, Donna E. Hogge, MD

Blood (2007) 110 (11): 894.

https://doi.org/10.1182/blood.V110.11.894.894

Published: 2007

Journal Articles

Expression of interleukin-3 receptor subunits on defined subpopulations of acute myeloid leukemia blasts predicts the cytotoxicity of diphtheria toxin interleukin-3 fusion protein against malignant progenitors that engraft in immunodeficient mice

Leman Yalcintepe, Arthur E. Frankel, Donna E. Hogge

Blood (2006) 108 (10): 3530–3537.

https://doi.org/10.1182/blood-2006-04-013813

Published: 2006

Journal Articles

Diphtheria toxin fused to variant human interleukin-3 induces cytotoxicity of blasts from patients with acute myeloid leukemia according to the level of interleukin-3 receptor expression

Ugo Testa, Roberta Riccioni, Mauro Biffoni, Daniela Diverio, Francesco Lo-Coco, Robin Foà, Cesare Peschle, Arthur E. Frankel

Blood (2005) 106 (7): 2527–2529.

https://doi.org/10.1182/blood-2005-02-0540

Published: 2005

Journal Articles

A Phase II Study of Denileukin Diftitox (ONTAK R ) in Patients with Fludarabine Refractory B-Cell Chronic Lymphocytic Leukemia.

Philip Kuriakose, MD, Francesco Turturro, MD, Jesus G. Berdeja, MD, Robert Kerr, MD, Asha Surendranathan, Jennifer Black, Arthur E. Frankel, MD

Blood (2004) 104 (11): 4824.

https://doi.org/10.1182/blood.V104.11.4824.4824

Published: 2004

Journal Articles

Variant Forms of Human Interleukin-3 (IL-3) Linked to Truncated Diphtheria Toxin (DT 388 ), Have Enhanced Cytotoxicity Against Acute Myeloid Leukemia (AML) Progenitors.

Siaw Hui Wong, Arthur E. Frankel, MD, Donna E. Hogge, MD,Ph.D

Blood (2004) 104 (11): 1797.

https://doi.org/10.1182/blood.V104.11.1797.1797

Published: 2004

Journal Articles

A urokinase-activated recombinant diphtheria toxin targeting the granulocyte-macrophage colony-stimulating factor receptor is selectively cytotoxic to human acute myeloid leukemia blasts

Ralph J. Abi-Habib, Shihui Liu, Thomas H. Bugge, Stephen H. Leppla, Arthur E. Frankel

Blood (2004) 104 (7): 2143–2148.

https://doi.org/10.1182/blood-2004-01-0339

Published: 2004

Journal Articles

Enhanced ceramide generation and induction of apoptosis in human leukemia cells exposed to DT 388 –granulocyte-macrophage colony-stimulating factor (GM-CSF), a truncated diphtheria toxin fused to human GM-CSF

Alex Senchenkov, Tie-Yan Han, Hongtao Wang, Arthur E. Frankel, Timothy J. Kottke, Scott H. Kaufmann, Myles C. Cabot

Blood (2001) 98 (6): 1927–1934.

https://doi.org/10.1182/blood.V98.6.1927

Published: 2001

NARROW

North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Large Single-Center Experience: Analysis of Clinical and Molecular Characteristics and Patient Outcomes

Safety and Efficacy of AG-221, a Potent Inhibitor of Mutant IDH2 That Promotes Differentiation of Myeloid Cells in Patients with Advanced Hematologic Malignancies: Results of a Phase 1/2 Trial

Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients

Preclinical Studies Of SL-401, a Targeted Therapy Directed To The Interleukin-3 Receptor (IL3-R), In Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Potent Activity In BPDCN Cell Lines, Primary Tumor, and In An In Vivo Model

An Update On The Robust Clinical Activity Of SL-401, a Targeted Therapy Directed To The Interleukin-3 Receptor On Cancer Stem Cells and Tumor Bulk, In Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

An Update On The Clinical Activity Of Resimmune, a Targeted Therapy Directed To CD3 Receptor, In Patients With Cutaneous T Cell Lymphomas--CTCL

SL-401, A Targeted Therapy Directed to the Interleukin-3 Receptor Present On Leukemia Blasts and Cancer Stem Cells, Is Active As a Single Agent in Patients with Advanced AML

The IL-3Rα-Targeted Drug SL-401 Selectively Kills Blastic Plasmacytoid Dendritic Cell Neoplasm Cells

IL3R Directed Agents, SL-401 and SL-501, Inhibit the Growth of Leukemia Stem Cells In CML.

Phase I Trial Results for SL-401, a Novel Cancer Stem Cell (CSC) Targeting Agent, Demonstrate Clinical Efficacy at Tolerable Doses In Patients with Heavily Pre-Treated AML, Poor Risk Elderly AML, and High Risk MDS

Targeting IL3 Receptor in Chronic Myeloid Leukemia.

Phase I Study Demonstrates Activity and Tolerability of Diphtheria Toxin Interleukin-3 Fusion Protein in Patients with AML and MDS.

Expression of interleukin-3 receptor subunits on defined subpopulations of acute myeloid leukemia blasts predicts the cytotoxicity of diphtheria toxin interleukin-3 fusion protein against malignant progenitors that engraft in immunodeficient mice

Diphtheria toxin fused to variant human interleukin-3 induces cytotoxicity of blasts from patients with acute myeloid leukemia according to the level of interleukin-3 receptor expression

A Phase II Study of Denileukin Diftitox (ONTAK R ) in Patients with Fludarabine Refractory B-Cell Chronic Lymphocytic Leukemia.

Variant Forms of Human Interleukin-3 (IL-3) Linked to Truncated Diphtheria Toxin (DT 388 ), Have Enhanced Cytotoxicity Against Acute Myeloid Leukemia (AML) Progenitors.

A urokinase-activated recombinant diphtheria toxin targeting the granulocyte-macrophage colony-stimulating factor receptor is selectively cytotoxic to human acute myeloid leukemia blasts

Enhanced ceramide generation and induction of apoptosis in human leukemia cells exposed to DT 388 –granulocyte-macrophage colony-stimulating factor (GM-CSF), a truncated diphtheria toxin fused to human GM-CSF

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only